A drug safety evaluation of risankizumab for psoriasis

References

• Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Wang TS, Hsieh CF, Tsai TF. Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: a nationwide, population-based observational study in Taiwan. J Dermatol Sci. 2016;84(3):340–345.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Rendon A, Psoriasis Pathogenesis SK. Treatment. Int J Mol Sci. 2019;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–694.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Gooderham M, et al. Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial. Br J Dermatol. 2017;177(5):e248.
   Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kellner H, Morita A, et al. Efficacy and safety of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis. 2018;77:200–201.
   Web of Science ®Google Scholar
• McKeage K, Duggan SJD. Risankizumab: first global approval. Drugs. 2019;79(8):893–900.
   PubMed Web of Science ®Google Scholar
• Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119.
   PubMed Web of Science ®Google Scholar
• Yoon J, Leyva-Castillo JM, Wang G, et al. IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization. J Exp Med. 2016;213(10):2147–2166.
   PubMed Web of Science ®Google Scholar
• Eberle FC, Bruck J, Holstein J, et al. Recent advances in understanding psoriasis. F1000Res. 2016;5:770.
   Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
   PubMed Web of Science ®Google Scholar
• Banaszczyk K. Risankizumab in the treatment of psoriasis - literature review. Reumatologia. 2019;57(3):158–162.
   PubMedGoogle Scholar
• Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37(10):2695–2706.
   PubMed Web of Science ®Google Scholar
• Kagami S, Rizzo HL, Kurtz SE, et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010;185(9):5453–5462.
   PubMed Web of Science ®Google Scholar
• Deepe, Jr. GS Jr., Gibbons RS. Interleukins 17 and 23 influence the host response to histoplasma capsulatum. J Infect Dis. 2009;200(1):142–151.
   PubMed Web of Science ®Google Scholar
• Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361(18):1760–1767.
   PubMed Web of Science ®Google Scholar
• Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361(18):1727–1735.
   PubMed Web of Science ®Google Scholar
• Domingues-Ferreira M, Grumach AS, Duarte AJ, et al. Esophageal cancer associated with chronic mucocutaneous candidiasis Could chronic candidiasis lead to esophageal cancer? Med Mycol. 2009;47(2):201–205.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ghislain P, Kerdel F, et al. Efficacy of risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. Exp Dermatol. 2019;28(3):e25.
   Web of Science ®Google Scholar
• Strober B, Lambert J, Gu Y, et al. Impact of prior treatment history on efficacy of risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. Exp Dermatol. 2019;28(3):e24.
   Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab: results from two double-blind, placebo-and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis. Acta Derm Venereol. 2018;98:28–29.
   Web of Science ®Google Scholar
• Leonardi C, Bachelez H, Wu JJ, et al. Safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled short-term and long-term clinical trial data. 24th World Congress of Dermatology; 2019 Jun 10- 15;Milan,Italy.
   Google Scholar
• Khatri A, Cheng L, Camez A, et al. Lack of effect of 12-week treatment with risankizumab on the pharmacokinetics of cytochrome P450 probe substrates in patients with moderate to severe chronic plaque psoriasis. Clin Pharmacokinet. 2019;58(6):805–814.
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–1560.
   PubMed Web of Science ®Google Scholar
• Khatri A, Suleiman AA, Polepally AR, et al. Exposure-response relationships for efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis: integrated analyses of phase 2 and 3 clinical trials. J Am Acad Dermatol. 2019;81(4):AB209.
   Web of Science ®Google Scholar
• Bachelez H, Gordon K, Blauvelt A, et al. Short-and long-term safety of risankizumab in patients with moderate-to-severe psoriasis: an integrated analysis. J Eur Acad Dermatol Venereol. 2019;33:37–38.
   Google Scholar
• Strober B, Blauvelt A, Menter A, et al. Risankizumab treatment is associated with low and consistent infection rates over time in patients with moderate to severe psoriasis: analysis of pooled clinical trial data. American Academy of Dermatology Annual Meeting; 2019 Mar 1–5;Washington, DC.
   Google Scholar
• Langley RG, Blauvelt A, Gooderham M, et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance trial. American Academy of Dermatology Annual Meeting; 2019 Mar 1-5; Washington, DC.
   Google Scholar
• Reich K, KB G, Tyring S, et al. Malignancy rates in patients with moderate to severe psoriasis during treatment with risankizumab: analysis of pooled clinical trial data. Am Acad Dermatol. 2019;81(4,1):AB91.
   Google Scholar
• Reich K, Gordon KB, Tyring S, et al. Malignancy rates in patients with moderate to severe psoriasis treated with risankizumab: analysis of pooled short-term and long-term clinical trial data. 24th World Congress of Dermatology; 2019 Jun 10-15; Milan,Italy.
   Google Scholar
• Leonardi C, Bachelez H, Wu JJ, et al. Long-term safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled clinical trial data. J Am Acad Dermatol. 2019;81(4):AB234.
   Google Scholar
• Khatri A, Suleiman AA, Polepally AR, et al. Exposure‐response relationships for efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis: integrated analyses of phase 2 and 3 clinical trials. American Academy of Dermatology Annual Meeting; 2019 Mar 1-5; Washington DC.
   Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Trigoni A, et al. Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events. J Eur Acad Dermatol Venereol. 2013;27(12):1586–1587.
   PubMed Web of Science ®Google Scholar
• Reich K, Cem G, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2019. DOI:10.1016/j.jaad.2019.11.040.
   Web of Science ®Google Scholar
• Shim HH, Cai SCS, Chan W, et al. Mycobacterium abscessus infection during ustekinumab treatment in crohn’s disease: a case report and review of the literature. J Crohns Colitis. 2018;12(12):1505–1507.
   PubMed Web of Science ®Google Scholar
• Hsiao CY, Chiu HY, Wang TS, et al. Serial QuantiFERON-TB gold testing in patients with psoriasis treated with ustekinumab. PLoS One. 2017;12(9):e0184178.
   PubMed Web of Science ®Google Scholar
• Lynch M, Roche L, Horgan M, et al. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017;3(3):230–232.
   PubMedGoogle Scholar
• Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24(4):508–509.
   PubMed Web of Science ®Google Scholar
• Sanchez-Moya AI, Dauden E. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment. Arch Dermatol. 2012;148(11):1332–1333.
   PubMedGoogle Scholar
• Ardain A, Domingo-Gonzalez R, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019;570(7762):528–532.
   PubMed Web of Science ®Google Scholar
• Boisson-Dupuis S, Ramirez-Alejo N, Li Z, et al. Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant. Sci Immunol. 2018;3(30):eaau8714.
   PubMed Web of Science ®Google Scholar
• Martinez-Barricarte R, Markle JG, Ma CS, et al. Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol. 2018;3(30):eaau6759.
   PubMed Web of Science ®Google Scholar
• Kammuller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased mycobacterium tuberculosis infections. Clin Transl Immunology. 2017;6(8):e152.
   PubMedGoogle Scholar
• Wu CY, Chiu HY, Tsai TF. The seroconversion rate of QuantiFERON-TB Gold in-tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLoS One. 2019;14:e0225112.
   Web of Science ®Google Scholar
• Malatestinic W, Nordstrom B, Wu JJ, et al. Characteristics and medication use of psoriasis patients who may or may not qualify for randomized controlled trials. J Manag Care Spec Pharm. 2017;23(3):370–381.
   PubMedGoogle Scholar
• Masson Regnault M, Castaneda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the french psoriasis registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2019. DOI:10.1111/jdv.15878.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376(20):1989–1991.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chiu YM, Chang Liao NF, et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: A nine-year multicenter cohort study. J Am Acad Dermatol. 2019. DOI:10.1016/j.jaad.2019.12.001.
   Google Scholar
• Tsai TF. Hepatitis B virus reactivation after ustekinumab treatment: reply from authors. Br J Dermatol. 2014;170(2):478–479.
   PubMed Web of Science ®Google Scholar
• Cho YT, Chen CH, Chiu HY, et al. Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol. 2012;39(3):269–273.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Failla V, Nikkels AF. Ustekinumab and herpes zoster. Dermatology. 2011;222(2):119–122.
   PubMed Web of Science ®Google Scholar
• Stollberger C, Finsterer J. Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis. J Dermatol. 2017;44(6):703–705.
   PubMed Web of Science ®Google Scholar
• Lee MG, Huang YH, Lee JH, et al. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: subgroup analysis from the CLEAR study. J Dermatol. 2019;46(9):752–758.
   PubMed Web of Science ®Google Scholar
• Anderson ME, Queen D, Vance SL, et al. Ustekinumab-associated disseminated verrucae. JAAD Case Rep. 2018;4(10):1030–1033.
   PubMedGoogle Scholar
• Chiu HY, Tsai TF. The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study. J Am Acad Dermatol. 2016;75(1):224–226.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chan CC, Tsai TF. The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis. Int J Dermatol. 2016;55(11):e600–e602.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839.
   PubMed Web of Science ®Google Scholar